No detrimental effect on renal function during long-term use of fluvastatin in renal transplant recipients in the Assessment of Lescol in Renal Transplantation (ALERT) study

Clinical Transplantation

Volumn 20, Issue 6, 2006, Pages 732-739

  Fellström, Bengt ^a   Abedini, Sadollah ^b   Holdaas, Hallvard ^b   Jardine, Alan G ^c   Staffler, Beatrix ^d   Gimpelewicz, Claudio ^d  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Adverse effects; Creatinine; Diabetes mellitus; Fluvastatin; Kidney; Transplantation

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CARDIOVASCULAR AGENT; CORTICOSTEROID DERIVATIVE; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PREDNISOLONE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT RECIPIENT; HEART DISEASE; HUMAN; INCIDENCE; KIDNEY DISEASE; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL GRAFT DYSFUNCTION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; AGED; ANTIOXIDANTS; CREATINE; DOUBLE-BLIND METHOD; EUROPE; FATTY ACIDS, MONOUNSATURATED; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INCIDENCE; INDOLES; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROTEINURIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 33750821478     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2006.00555.x     Document Type: Article

References (22)

1. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003: 326: 1423.
2. Agarwal R. Statin induced proteinuria: Renal injury or renoprotection? J Am Soc Nephrol 2004: 15: 2502.
3. Deslypere JP, Delanghe J, V ermeulen A. Proteinuria as complication of simvastatin treatment. Lancet 1990: 336: 1453.
4. Vidt DG, Cressman MD, Harris S, Pears JS, Hutchinson HG. Rosuvastatin-induced arrest in progression of renal disease. Cardiology 2004: 102: 52.
5. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003: 361: 2005.
6. Athyros VG, Mikhailidis DP, Papageorgiou AA et.al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004: 57: 728.
7. Lemos PA, Serruys PW, De Feyter P et.al. Long-term fluvastatin reduces the hazardous effect of renal impairment on 4-year atherosclerotic outcomes (a LIPS substudy). Am J Cardiol 2004: 95: 445.
8. Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: A meta-analysis. Kidney Int 2001: 59: 260.
9. Holdaas H, Fellstrom B, Holme I et.al. Effects of fluvastatin on cardiac events in renal transplant patients: ALERT (Assessment of Lescol in Renal Transplantation) study design and baseline data. J Cardiovasc Risk 2001: 8: 63.
10. Holdaas H, Fellstrom B, Jardine AG et.al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial. Lancet 2003: 361: 2024.
11. Fellstrom B, Holdaas H, Jardine AG et.al. Effect of fluvastatin on renal end points in the Assessment of Lescol in Renal Transplant (ALERT) trial. Kidney Int 2004: 66: 1549.
12. Viberti GC. Diabetic renal disease in type 1 diabetes: Aetiology and prevention. Diabet Med 1991: 8: S38.
13. Ritz E, Keller CK, Bergis KH, Siebels M. Renal involvement in type II diabetes. Curr Opin Nephrol Hypertens 1994: 3: 137.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976: 16: 31.
15. Fellstrom BC, Larsson E. Pathogenesis and treatment perspectives of chronic graft rejection (CVR). Immunol Rev 1993: 134: 83.
16. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985: 33: 278.
17. Tonolo G, Melis MG, Formato M et.al. Additive effects of Simvastatin beyond its effects on LDL cholesterol in hypertensive type 2 diabetic patients. Eur J Clin Invest 2000: 30: 980.
18. Sasaki T, Kurata H, Nomura K, Utsunomiya K, Ikeda Y. Amelioration of proteinuria with pravastatin in hypercholesterolemic patients with diabetes mellitus. Jpn J Med 1990: 29: 156.
19. Ballantyne CM, Corsini A, Davidson MH et.al. Risk for myopathy with statin therapy in high-risk patients. Arch Intern Med 2003: 163: 553.
20. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc Drugs Ther 2003: 17: 265.
21. Benghozi R, Bortolini M, Jia Y, Isaacsohn JL, Troendle AJ, Gonasun L. Frequency of creatine kinase elevation during treatment with fluvastatin. Am J Cardiol 2002: 89: 231.
22. Bostom AG, Kronenberg F, Ritz E. Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. J Am Soc Nephrol 2002: 13: 2140.